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Background: There is a plethora of assessment tools available to measure breathlessness,
the most common and disabling symptom of advanced cardio-respiratory disease. The aim
of this systematic review was to identify all measures available via standard search
techniques and review their usefulness for patients with advanced disease.
Methods: A systematic literature search was performed in Medline. All studies focusing on
the development or evaluation of tools for measuring breathlessness in chronic respiratory
disease, cardiac disease, cancer, or MND were identified. Their characteristics with regard
to validity, reliability, appropriateness and responsiveness to change were described. The
tools were then examined for their usefulness in measuring significant aspects of
breathlessness in advanced disease.
Results: Thirty-five tools were initially identified, two were excluded. Twenty-nine were
multidimensional of which 11 were breathlessness-specific and 18 disease-specific. Four
tools were unidimensional, measuring the severity of breathlessness. The majority of
disease-specific scales were validated for chronic obstructive pulmonary disease (COPD),
few were applicable in other conditions. No one tool assessed all the dimensions of this
complex symptom, which affects the psychology and social functioning of the affected
individual and their family—most focused on physical activity.
Conclusion: As yet there is no one scale that can accurately reflect the far-reaching
effects of breathlessness on the patient with advanced disease and their family. Therefore,
at present, we would recommend combining a unidimensional scale (e.g. VAS) with aElsevier Ltd. All rights reserved.
of Palliative Care, Policy and Rehabilitation, King’s College London, Weston Education Centre, Denmark
UK. Tel.: +44 20 7848 5518; fax: +44 20 7848 5517.
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C. Bausewein et al.400disease-specific scale (where available) or a multidimensional scale in conjunction with
other methods (such as qualitative techniques) to gauge psychosocial and carer distress for
the assessment of breathlessness in advanced disease.
& 2006 Elsevier Ltd. All rights reserved.Contents
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Breathlessness is a complex symptom affecting many dimen-
sions of a patient’s life reducing not only patients’ activity
and functional capacity, but also causing distress and
discomfort. Despite the many advances that have taken
place in cardio-respiratory medicine in recent years, the
breathlessness that accompanies advanced disease fre-
quently remains intractable causing distress and disability
for patients and anxiety and social isolation for their close
family. There is a need for carefully developed studies with
clearly defined research questions and appropriate measure-
ment tools to evaluate ways of improving patients’ breath-
lessness. Historically, most of the work on the measurement
of breathlessness has been conducted by respiratory clin-
icians and physiologists, therefore most measures have been
developed for patients with chronic pulmonary disease1,2 and
are suitable for use only in a clinical setting. To date,
palliative care studies have focused on the management of
breathlessness rather than its assessment, but improving the
management of breathlessness requires assessment tools,
which are sensitive enough to accurately assess the effect of
interventions intended to relieve the symptom.1Patients experience different sensations with various
intensities when they describe breathlessness. The Amer-
ican Thoracic Society (ATS) stresses that breathlessness is a
subjective symptom, like pain, which can only be described
and interpreted by the patient and therefore any assess-
ment should be patient-reported.3 Severity, character, time
course and triggers have also to be taken into account as the
course of breathlessness varies with different disease
trajectories such as cancer, chronic obstructive pulmonary
disease (COPD) or motor neurone disease (MND). Further
measurable aspects are symptom frequency, severity and
distress and the symptom’s impact on function, psychologi-
cal, social and spiritual well-being.
The aim of this paper is to identify and systematically
review the literature for instruments regularly used
to measure the sensation of breathlessness in chronic
conditions such as COPD, cancer, chronic heart failure and
MND. A second aim is to relate these tools to the specific
situation of patients with advanced disease and identify
those measures that could be used by patients near the end
of life.
The review focuses on measures of the sensation of
breathlessness. Health-related quality-of-life measures,
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as the Memorial Symptom Assessment Schedule,4 the
Edmonton Symptom Assessment Schedule (ESAS)5 and the
Support Team Assessment Schedule (STAS),6 which are also
regularly used with breathless patients are not the subject
of this review. In addition, pulmonary function and exercise
testing are not included because they do not assess the
severity of the feeling of being breathless (i.e. the
sensation) but rather the impact of breathlessness on
functional capacity (exercise testing) or the physiological
consequences of the underlying illness causing breathless-
ness.
Methods
Definition of breathlessness
There are a variety of definitions of breathlessness ranging
from two words (e.g. ‘‘laboured breathing’’) to whole
paragraphs, but no consensus exists on a single one. The
ATS has defined breathlessness, or dyspnoea, as ‘‘a
subjective experience of breathing discomfort that is
comprised of qualitatively distinct sensations that vary in
intensity’’.3 For the purpose of this review the ATS definition
will be used and we will refer to ‘breathlessness’, as
opposed to ‘dyspnoea’, as this is the term patients use.
Definition of advanced disease
‘‘Advanced’’ stages of disease are often not clearly defined.
Generally the term ‘‘advanced’’ is connected with active
and progressive disease and a limited prognosis. Prognos-
tication in advanced disease relates to different factors such
as symptoms, performance status and disease trajectory. As
disease trajectories vary depending on whether the patient
is suffering from malignant or non-malignant disease,7
advanced stages have to be defined independently for every
disease. Breathlessness is known to be one of the symptoms
that increase towards the dying phase in cancer patients.8–10
Literature search
A systematic literature search was performed.11 MEDLINE
(1966–August 2005 week 1) was searched using OVID with
the following search terms: dyspnoea/dyspnea (MeSH
exploded and keyword) or breathlessness (keyword) AND
outcome measures (keyword) or outcome assessment
(health care) (exploded) or treatment outcome (keyword)
or treatment outcome (exploded) or psychometrics (key-
word) or psychometrics (exploded) or questionnaires (key-
word) or questionnaires (exploded) or medical audit
(exploded) or audit measures (keyword) or outcome (key-
word) or quality of health care (exploded). The reference
lists of all retrieved studies and review articles were
searched for further relevant articles.
Selection criteria
The following criteria for the selection of studies were used:
studies focusing on the development or evaluation ofinstruments measuring the sensation of breathlessness in
chronic respiratory disease, cardiac disease, cancer or MND.
Measurement could relate to severity, intensity or exercise
capacity, and be uni- or multidimensional. Multidimensional
tools were included if they were breathlessness specific or
disease specific. Similarly, measures assessing quality of life
were included if they contained questions relating to
breathlessness and were clearly related to one of the
above-mentioned conditions. General health-related mea-
sures, domain-specific measures or general symptom mea-
sures were not included as was information on
breathlessness and posture because it did not seem relevant
to this review.
Data extraction and analysis
Identified measures were first evaluated according to the
criteria listed in Table 1. These criteria are relevant for
psychometric testing of outcome measures, as used in other
reviews.12,13 In a second step the identified measures were
examined according to their potential for use in patients
with advanced disease. The following criteria were adopted:
(1) content of the measure regarding breathlessness
(severity, frequency, intensity and distress) and symptoms/
factors (physical, function, psychosocial and spiritual) and
(2) administration of the measure (self-administration,
time, validated in advanced disease, frequency of use).
The frequency of use was evaluated with a cut-off point of
five studies indicating frequent use.
Results
The search yielded 6330 references. Seventy-three studies
were identified that reported either the development and/
or validation of 35 instruments measuring breathlessness.
We excluded two instruments, the COPD Activity Rating
Scale14 and the Breathing Problems Questionnaire,15 as they
mainly measured functional impairment of patients with
breathlessness and did not contain any questions evaluating
breathlessness itself.
Of the remaining measures, 29 were multidimensional, of
which 11 were breathlessness-specific and 18 were disease-
specific. Four were unidimensional, measuring the severity
of breathlessness (Fig. 1). The psychometric properties of
the included measures are shown in Appendix A.
Unidimensional tools
Three types of unidimensional instruments are commonly
used in the measurement of breathlessness (Appendix A):
visual analogue scales (VAS), numerical rating scales (NRS)
and the Modified Borg Scale. Unidimensional tools measure
breathlessness in general or on exercise (e.g. Oxygen Cost
Diagram and Modified Borg Scale16,17) and are often used to
describe the severity of breathlessness in exercise tolerance
tests. Many tools developed for patients with advanced
disease use VAS (e.g. ESAS5), NRS or categorical scales (e.g.
STAS6). All unidimensional measures are self-administered
and quick to complete. The VAS, the Modified Borg Scale and
the Oxygen Cost Diagram are frequently used (more than
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Table 1 Criteria for the evaluation of breathlessness measures.
Validity
Content validity Does the measure cover domains of importance to patients and caregivers?
Criterion validity Does the measure correlate with superior measures or predicted futures outcomes?
Construct validity Do the results confirm expected pattern of relationships or hypotheses?
Reliability
Internal consistency Do individual items within measure correlate with each other and with total scores?
Test–retest reliability Does the measure produce same results when applied under same conditions at different
times?
Responsiveness to change
and acceptability
Does the measure discriminate between differing degrees of disease severity?
Has the measure demonstrated change in clinical trials or follow-up studies?
Are observed scores well distributed around scale midpoint, with low floor and ceiling effects?
Appropriateness
Is the measure suitable for use in clinical audit in a variety of settings?
Is the amount of time needed for completion acceptable?
6330 references
73 studies measuring
breathlessness
35 instruments related
to breathlessness
33 included 2 excluded
29 multidimensional 4 unidimensional
11 breathlessness-
specific
18 disease-
specific 
Figure 1
C. Bausewein et al.402five studies) in studies including patients suffering from
breathlessness.VAS
The VAS is widely used in the measurement of breathlessness
as well as other symptoms, e.g. pain, at a specific point in
time. Numerous studies have established its validity,
whether as a measure of breathlessness or other sensa-
tions18–22; however, comparison of studies is difficult due to
the use of different formats, lack of specification of
formats, small sample numbers and the use of the scale to
measure different variables,1 e.g. different aspects of
breathlessness such as ‘breathlessness’, ‘distress due to
breathlessness’ or ‘bother caused by breathlessness’. Heyse-Moore23 validated a VAS relating to the preceding 24 h
(VAS24). There are no apparent criteria or standard
principles that guide the consistent use of the VAS by
different observers.24 As breathlessness is a sensation that
can change between measurements, the VAS is most suited
to within-subject repeated measurement as it has the
sensitivity required to measure minute changes.1 It is not
suitable, however, for comparing breathlessness in different
patients, nor would it be satisfactory for summarising or
comparing the conditions of groups of patients.24 Dudgeon
compared a VAS with a verbal rating scale for dyspnoea and
showed that the two scales had a strong correlation to the
point of redundancy.25Oxygen-cost diagram
The oxygen-cost diagram (OCD) is a variation of the VAS.16
Guyatt described the diagram as ‘simple and easy to
administer’26; however, Mahler and Wells reported initial
difficulties with patients’ lack of understanding of how to
use it.27 Ambrosino and Porta noted that not all patients
engaged in all the activities depicted along the line.24 In
addition, the measure relies heavily on ambulatory activ-
ities so it is of limited use for assessing patients who are
breathless at rest. It offers no advantages over the VAS1 and
its responsiveness and validity are unproven.26 The OCD has
been widely used in patients with pulmonary disease but not
in patients with advanced cancer or other diseases.NRS
From pain management it is known that NRSs are easier to
use for patients than VASs.28 In the measurement of
breathlessness, ratings on the NRS are highly correlated
with VAS ratings.29 The NRS has been shown to be a more
repeatable measure than the VAS, therefore requiring
smaller sample sizes to detect a change in breathlessness.30
Subratty developed an NRS for the assessment of breath-
lessness in chronic heart failure and related it to a list of
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patients.31
Modified Borg Scale
The Borg Scale was developed to assess the rate of
perceived exertion.32 Later the instrument was used to
measure the intensity of the sensation of breathlessness
(originally in healthy subjects on exercise); now the
Modified Borg Scale is the format most commonly used.17,32
Although not a true ratio scale, it has been described as such
to enable statistical calculations1 but is more appropriately
described as a categorical scale33 or a ‘category scale with
ratio properties’.34 Wilson and Jones demonstrated that
Modified Borg Scale scores are more reproducible than VAS
scores between tests and within the period of a single
exercise test.18 The Borg Scale has, in comparison to the
VAS, the advantage that it can be used over the phone.
Ambrosino and Porta recommended using a modified Borg
score for each level of effort during a scalar test, and
comparing the severity of breathlessness at comparable
time periods (isotime) or at similar work intensities (iso-
load).24 Further work is required to assess its usefulness in
patients with advanced cancer.1,34
Breathlessness-specific tools
We identified 11 breathlessness-specific tools (Appendix A),
covering the following domains: magnitude of task23,35,36;
magnitude of effort and functional impairment35; symptoms
associated with breathlessness37–40; activities of daily living
and fear of overexertion41; breathlessness during physical
activity, speaking activity and speaking during physical
activity42; sense of effort, sense of anxiety, sense of
discomfort43; frequency, timing, triggers, coping strategies,
limitations, feelings40; intensity, temporal, constrictive
pressure, pain, sound quantity, dry sound, wet sound,
energy, air quantity, respiratory effort, loss of power, fear,
depression, dread, suffocation, illness.23 Of these tools only
the Modified MRC Dyspnoea Scale and the Baseline/Transi-
tion Dyspnoea Index are used in more than five studies.
All but five of the breathlessness-specific tools have been
validated in patients with pulmonary disease, predominantly
COPD. Only one scale, the Feinstein Index of Dyspnoea, has
been validated for patients with chronic heart failure.38 The
Cancer Dyspnoea Scale (CDS43), the Dyspnoea Exertion Scale
and the Dyspnoea Assessment Questionnaire23 have been
validated for patients with cancer. The Breathlessness
Assessment Guide was developed for patients with lung
cancer.40
Six of these measures are self-administered: the Breath-
lessness Cough and Sputum Scale (BCSS39), the Chronic Lung
Disease Severity Index,37 the University of California St.
Diego Shortness of Breath Questionnaire,41 the University of
Cincinnati Dyspnea Questionnaire42 and the CDS.43 Fein-
stein’s Index of Dyspnoea,38 the Breathlessness Assessment
Guide40 and the Baseline Dyspnoea Index/Transition Dys-
pnoea Index (BDI/TDI)35 are administered by an interviewer
but a self-administered computerised format of the BDI has
been developed.44 Two measures, the MRC Dyspnoea Scale36
and the University of Cincinnati Dyspnoea Questionnaire,42
have a format that allows either self-administration orinterviewer administration. The tools contain between
three and 30 items, and the reported completion time
varies from 30 s (Medical Research Council (MRC) Dyspnoea
Scale36) to 5–10min (University of Cincinnati Dyspnoea
Questionnaire42).
Most breathlessness-specific tools have been successfully
tested for validity and reliability in patients with COPD with
the exception of the Breathlessness Assessment Guide,40
which has not yet undergone formal psychometric testing.
Responsiveness and appropriateness have not been shown
for all scales. The MRC Dyspnoea Scale is too insensitive to
capture relevant changes in breathlessness following an
intervention45,46 whereas the BDI/TDI have been specifically
developed to measure changes from the baseline condi-
tion.35 The BDI/TDI was found to obtain valid, responsive
measures of acute changes in quality of life and breath-
lessness associated with a COPD exacerbation.47 The BCSS
showed discriminative quality and was responsive to change,
as was the CDS.39,48 Stoller et al. developed a Modified
Baseline Dyspnoea Index to provide more precise criteria for
the ratings by differentiating between home and work
functional impairment.49 However, it does not demonstrate
any advantage to Mahler’s index when using the tool to
assess breathlessness in patients with end stage disease who
are no longer able to work.1Disease-specific dyspnoea tools
We identified 18 multidimensional disease-specific tools
(Appendix A) of which the Chronic Respiratory Disease
Questionnaire (CRQ50) is one of the most widely used
measures for quality of life in chronic respiratory disease.51
Most of them aim to assess the quality of life of patients with
respiratory disease by covering the varying combinations of
some of the following domains: emotional and mental
function, mastery, coping skills, concerns, depression,
anxiety50,52–59; symptoms such as cough, sputum, breath-
lessness, fatigue50,52,53,53,53,60; physical activity52,55–57,61–64;
impact on daily life50,53,58,60; self-care, domestic, lei-
sure53,61,65; social activity and limitations53,55,58,59; sexual
functioning,66 environmental stimuli;57 treatment satisfac-
tion56 and quality of life.63
The identified measures cover between eight and 164
items, with a completion time of between 2min (Clinical
COPD Questionnaire (CCQ)52) and 15–25min (CRQ50). Seven
of the measures are self-administered: St. George’s Re-
spiratory Questionnaire, Seattle Obstructive Lung Disease
Questionnaire (SOLDQ), CCQ, Pulmonary Function Status
Scale (PFSS), 10-item Respiratory Illness Questionnaire (RIQ-
MON 10), VAS8, MND Dyspnoea Rating Scale
(MDRS)52,54,56,59,60,66,67. The Lung Cancer Symptom Scale
(LCSS) consists of two scales, one for the patient and one for
the health-care professional.63 In this group, the CRQ, the
St. George’s Respiratory Questionnaire, The Seattle Ob-
structive Lung Disease Questionnaire, the LCSS and the
Revised ALS Functional Rating Scale (ALSFRS-R) were used in
more than five studies.
The CRQ is an interviewer-administered questionnaire but
Schu¨nemann et al. showed that the self-administered
version maintains validity and responsiveness relative to
the interviewer-administered version.51 The CRQ is one of
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Table 2 Breathlessness measures and advanced disease.
Type, name (and abbreviation)
of measure
Content of measure Administration of measure
Breathlessness Symptoms/factors
Severity Frequency Intensity Distress Physical Functional Psychological Social Spiritual Self-admin. Validated in
advanced
disease
Time Frequency
of use
Unidimensional measures
Visual Analogue Scale (VAS)19,21,22 X X X Seconds X
Oxygen Cost Diagram (OCD)16 X X X 1–2min X
Modified Borg Scale17 X X No information X
Numerical Rating Scale (NRS)29 X X No information
Breathlessness-specific measures
Modified MRC dyspnoea scale36 X X 30 s X
Baseline/Transition Dyspnoea
Index (BDI/ TDI)35
X X Observer ¼ 5min;
self-admin ¼ no info
X
Breathlessness, Cough and
Sputum Scale (BCSS)39
X X X No information
Chronic Lung Disease severity
index (CLD)37
X X X X X No information
University of California St. Diego
(UCDS) Shortness of Breath
Questionnaire41
X X X X No information
University of Cincinnati Dyspnoea
Questionnaire42
X X X 5–10min
Feinstein’s Index of Dyspnoea38 X X X Few minutes
Cancer Dyspnoea Scale (CDS)43 X X X X X 140 s
Breathlessness Assessment Guide40 X X X X X X X X No information
Dyspnoea Exertion Scale23 X X X No information
Dyspnoea Assessment
Questionnaire23
X X X X No information
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Disease-specific measures
Chronic Respiratory Disease
Questionnaire (CRQ)50
X X X X X X First 15–25min (max
30), repeat 10–15
(max 20)
X
St. George’s Respiratory
Questionnaire (SGRQ)60
X X X X X X X No information X
MRC Respiratory Symptoms
Questionnaire36
X X X No information
ATS-DLD-78 questionnaire68 X X X No information
Seattle Obstructive Lung Disease
Questionnaire (SOLDQ)56
X X X X X X 5–10min X
Pulmonary Functional Status
Scale (PFSS)66
X X X X X 15min
London Chest Activity Daily
Living Scale65
X X X X
Pulmonary Function Status &
Dyspnoea Questionnaire (PFSDQ)61
X X X X X X First 17min, repeat 15
Modified PFSDQ (PFSDQ-M)62 X X X X X X First 7min, repeat 6
Airways Questionnaire 20 (AQ20)57 X X X X 2.570.9min
Clinical COPD Questionnaire
(CCQ)52
X X X X X X 2min approx.
Respiratory Quality of Life
Questionnaire (RQLQ)58
X X X X X X No information
Quality of Life for Respiratory
Illness Questionnaire (QOL-RIQ)55
X X X X X X No information
10-Item Respiratory Illness
Questionnaire-monitoring 10
(RIQ-MON 10)59
X X X X X Couple of minutes
VAS853 X X X X X X o5min
Lung Cancer Symptom Scale
(LCSS)63
X X X X Patients ¼ first 8min,
repeat 3–5;
observer ¼ 2min
X
MND Dyspnoea Rating Scale
(MDRS)54
X X X X X X X 10min
Revised ALS Functional rating
Scale (ALSFRS-R)64
X X X No information X
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patient’s point of view and its impact on quality of life,
demonstrating potential value as a tool in the initial
assessment of breathlessness. However, repeated use may
not detect small changes, limiting its application to patients
who develop breathlessness in their last few days.1
The MRC Respiratory Symptoms Questionnaire and the ATS
DLD-78 questionnaire are mainly used to assess the
prevalence of pulmonary disease in epidemiological stu-
dies68; however, they seem to be too coarse to demonstrate
reliable changes in breathlessness following intervention.45
Measurement of breathlessness in advanced disease
Table 2 shows how the identified measures relate to their
use in patients with advanced disease. Of the 33 instruments
evaluated, most are self-administered. Only three are
designed for use by an interviewer (BDI/TDI, Chronic
Respiratory Questionnaire, Breathlessness Assessment
Guide),35,50 of which two (BDI/TDI, CRQ) have a self-
administered version developed later.35,69 The severity of
breathlessness is measured in 25 instruments, the frequency
in ten, the distress in seven and the intensity in four.
Physical symptoms, predominantly other respiratory symp-
toms related to breathlessness such as cough or wheeze, are
included in 17 of the measures. The majority of the
instruments (28/33) contained questions related to the
functional status of the patient. Fifteen covered psycholo-
gical dimensions and 11 covered social dimensions. None of
the instruments included questions regarding the spiritual
dimension of breathlessness. Four breathlessness-specific
instruments were found to be validated for patients in a
palliative care setting: the CDS, the Breathlessness Assess-
ment Guide, the Dyspnoea Exertion Scale, and the Dyspnoea
Assessment Questionnaire.23,40,43 However all of these were
only for patients with malignant disease and have not been
tested in non-malignant progressive conditions. Twenty-one
of the identified measures were quick to fill in, most of them
taking between 5 and 10min. Ten measures have been
published in more than five studies.
Discussion
This is the first systematic review of the measurement of the
sensation of breathlessness in advanced disease (non-cancer
specific). We identified 33 instruments measuring breath-
lessness either unidimensionally, symptom specifically or
disease specifically. All measures but three met the criteria
of validity, reliability, responsiveness and appropriateness.
For the three measures missing psychometric data, in one it
had not been tested (Breathlessness Assessment Guide)40
and for the others the data are not available (Dyspnoea
Exertion Scale, Dyspnoea Assessment Questionnaire).23
From this review, it appears that there is no established
gold standard for the assessment of the impact of breath-
lessness in advanced disease. However, it remains unlikely
that any one instrument could be developed that would be
suitable for the clinically diverse population experiencing
this symptom in advanced disease. Instead, instruments
must be chosen from the existing pool by reference to a
series of operational criteria: the definition of breath-lessness being used, the setting of the study, temporal
factors, diagnostic group, disease staging and the sensitivity
required of the instrument.
The lack of a universal definition of breathlessness, or
dyspnoea, has lead to different and sometimes conflicting
results and conclusions.1 Many studies, particularly those
with cancer patients, do not state the definition they are
using9,70,71; however, a clear definition of breathlessness is
necessary for both the researcher and the patient. The
definition of the ATS is now widely used by many
researchers. Associations between different sensations of
breathlessness and specific underlying diseases have been
investigated; whilst no two conditions were linked to the
same group of descriptors, one group of descriptors could be
associated with more than one condition.2,72 It has also been
demonstrated that patients who deny being short of breath
will, on direct questioning, respond positively to other
descriptors.2 Whichever definition is chosen for use by
researchers in a particular study it needs to be comprehen-
sible to patients yet tightly defined for accurate measure-
ment.Available tools
Many tools are available for the measurement of breath-
lessness. However, this review confirms that there is no
single instrument that encompasses all the components of
the sensation of breathlessness.73 Different measures cover
one or more dimensions or aspects of breathlessness. Scales
developed for research rather than clinical measurement
provide valuable information on the perception of breath-
lessness, its impact on day-to-day life and factors which
exacerbate the symptom,35 but many are not sensitive
enough to detect small but significant changes that may
occur in the symptom in a patient with advanced disease. In
addition, a minimally clinically important difference has
been described for only some of these tools and for others
this information is not available. The unidimensional and
most of the breathlessness-specific tools are more suitable
for repeated measures than disease-specific tools as they
take only a short time to complete and have been shown to
be sensitive to change (see Appendix A). Disease-specific
measures are useful for the characterisation of patients as
they cover various aspects related to breathlessness.
The assessment tool should be chosen for the specific
research question being asked. In addition, the circum-
stances in which measurement is made must be clearly
defined: is breathlessness to be measured on exertion or at
rest? How is exertion defined? Over what period of time is
the measurement made? The following partially literature-
derived scenarios suggest how to combine tools according to
the research question: (i) in a RCT to determine the efficacy
of oral morphine in relieving the sensation of breathlessness
in patients dyspnoea was measured on a VAS with ‘‘no
breathlessness’’ at 0mm and ‘‘worst possible breathless-
ness’’ at 100mm as anchors, and exercise tolerance was
measured on the modified scale of the MRC74; (ii) in another
RCT that assessed the short-term clinical impact of
ambulatory oxygen over 12 weeks in dyspnoeic COPD
patients, dyspnoea was measured with a modified Borg
scale pre- and post-walk and the Chronic Respiratory
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study to describe the course of breathlessness over time in
COPD and cancer patients, a Modified Borg Scale is used in
combination with qualitative in-depth interviews to capture
both the severity of dyspnoea and the personal experience
of patients.
Population and conditions
Most instruments were validated for patients with pulmon-
ary disease, only a few were developed for patients with
cancer. Despite breathlessness being a common symptom in
chronic heart failure and MND, we identified only one
measure for the former and two for the latter condition.
Some tools are derived from instruments for patients with
asthma (AQ20, QoL-RIQ),55,76 or are validated in a variety of
pulmonary conditions (SGRQ, PFSDQ, BDI/TDI, CLD severity
index)35,37,60,61 but there is a lack of instruments that could
apply to a group of breathless patients with different
conditions. This makes research into a mixed patient group
challenging with regard to the choice of the measurement
tool. In addition, many measures for pulmonary conditions
are mainly validated in a predominantly male population
(BDI/TDI, CLD severity index, CDS, CRQ, PFSDQ, SOLDQ,
PFSS),35,37,43,50,56,61,66 which reflects the fact that COPD, in
particular, affects more men than women. However, it has
been shown that women perceive higher levels of breath-
lessness compared to men despite the same level of
ventilatory impairment.77,78 The generalisability of these
measures to a wider population could, therefore, be
questioned.
Most of the existing tools were not developed in the
palliative care setting and are not validated for patients
with advanced disease.
Unidimensional tools
Tools such as the VAS or the Modified Borg Scale appear
simple to use at first glance.35 Some patients will have used
VAS scales in pain management, but some still find them
difficult to use and confusing. Furthermore, there is
insufficient evidence to give unequivocal guidance and it
has yet to be defined what a clinically meaningful change is
on a VAS in breathlessness in COPD and cancer patients.79
From the measurement of breathlessness in decompensated
chronic heart failure and asthma it has been established that
a 2.11 cm change for the former and a 2.2 cm change for the
latter condition on a 10 cm VAS is meaningful.80,81 However,
a consensus statement from a recent meeting of specialists
researching breathlessness defined the best guess as a 10%
change (1 cm) in a VAS from baseline, or a 1-point change in
the BORG as a reasonable minimum for current use.79
Breathlessness-specific tools
Breathlessness-specific tools have the advantage of being,
on average, much shorter and therefore easier for patients
to complete than disease-specific tools. Some only cover
aspects of breathlessness (MRC Dyspnoea Scale, BDI/
TDI)35,36; others include symptoms related to breathlessness
such as cough and wheeze, which are typical for COPDpatients but not applicable in patients suffering from other
conditions. Only one instrument considers the impact of
breathlessness on speech (University of Cincinnati Dyspnoea
questionnaire),42,82 however speech, in this questionnaire,
is related to physical activity and daily activities, which may
not be applicable to patients in the advanced stage of their
disease.
The breathlessness-specific tools for patients with cancer
are all validated in a palliative care setting and in
consequence do not rely so much on functional status items
but on effort, discomfort, anxiety, frequency, triggers or
coping strategies. Unfortunately, the instrument that covers
most aspects and dimensions of breathlessness, the Breath-
lessness Assessment Guide,40 has not undergone the usual
psychometric testing examining validity and reliability of
the tool. In addition, its focus is on assessment rather than
responsiveness to treatment. Two further tools for cancer
patients have not been disseminated to a wider audience as
they have only been published within an MD thesis and have
not been validated in a standard way.23
Disease-specific tools
Disease-specific tools cover different aspects of the influ-
ence of breathlessness and the underlying disease on a
patient’s quality of life. Most disease-specific questionnaires
are similar, but each focuses on subtly different dimensions
or components deemed to be major concerns of patients.46
The majority of disease-specific tools are developed for
patients in COPD with the aim of showing treatment effects
in pulmonary rehabilitation and bronchodilator therapy. As
breathlessness reduces mobility, daily activities and self-
care, these domains are included in most of the instruments
validated for COPD patients. The functional domain also
plays a role in the two MND instruments; however, function
in this circumstance is related to much simpler tasks such as
talking, eating and dressing as patients’ functioning might
be affected by paralysis.
Exertion and function
In earlier stages of a disease, breathlessness is experienced
on exertion; later it is also experienced at rest. However,
exertion needs to be clearly defined for the patient group
under study, e.g. exertion could be defined as ten flights of
stairs or as the movement from the bed to the chair. Those
who might be breathless for small movements might also be
breathless at rest. Most instruments examining functional
status are not applicable for such patients as the examples
used for physical functioning include ‘‘walking uphill’’ or
‘‘heavy shopping’’ or ‘‘getting dressed’’ rather than small
movements around the bed or even ‘‘no movement at all’’.
In general, measuring breathlessness during exercise is
applicable to patients with stable COPD, but it is not useful
in advanced disease or terminal care.46
Measurement of breathlessness in advanced disease
Despite breathlessness being a frequent symptom towards
the end of life, only few measures have been developed and
validated for patients in this situation. There are more
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patients in palliative care. The available instruments are
either developed for the use in cancer (CDS, Breathlessness
Assessment Guide, Dyspnoea Exertion Scale, Dyspnoea
Assessment Questionnaire)23,40,43 or in MND.54,64 Despite
the fact that most tools have been developed for patients
with COPD there are none that have been explicitly
validated in patients in advanced disease. This might reflect
the difficulty of prognosis in COPD and the fact that these
patients tend not to decline as steadily as cancer patients.
With regard to the criteria important for symptom
measurement in palliative care, most instruments are self-
administered. However, some of them are quite lengthy and
therefore difficult for very ill patients to complete.
As already noted, measures rely heavily on functional
domains. No measure covers all dimensions important for
symptom control; however, breathlessness cannot be re-
garded as an isolated symptom.1 In COPD patients, breath-
lessness is often accompanied by other related respiratory
symptoms, such as cough or wheeze, which are reflected in
many tools developed for COPD. These symptoms might not
play such an important role in patients suffering from
cancer. Instead, cancer patients might experience many
other symptoms. Some of the cancer-specific tools such as
the LCSS and the Breathlessness Assessment Guide take
account of this.
Breathlessness is closely related to anxiety. However,
anxiety is only included in half of the breathlessness- and
disease-specific questionnaires. Surprisingly, the impact of
breathlessness on patients’ social lives is covered in an even
smaller number of questionnaires. However, it is known from
qualitative research in breathless patients that loss of social
life plays an important role for the patients.83 As the
experience of breathlessness also touches existential issues
it is disappointing that not one of the instruments covers this
dimension. Even the distress caused by breathlessness is
only covered in seven instruments. Distress should be given
greater consideration, especially in patients with advanced
disease who are close to death.
Recent research84 has uncovered the effect of intractable
breathlessness on those caring for or living with the patient
with this condition. Carer distress is one way of assessing
this and is not included in any of the instruments reviewed
here.
Conclusion
Although 33 tools for assessing breathlessness were identi-
fied, none were comprehensive or responsive enough to be
recommended for use in isolation to measure the sensation
of breathlessness, its impact on the quality of life of
patients with advanced disease and their family, nor its
response to treatment strategies. However, we can make
the following general recommendations: For general clinical questions (e.g. effectiveness of
medication) a VAS or the Modified Borg Scale are most
useful. Alternatively, if the focus is more on quality of life, then
a multidimensional tool (such as the CRQ for COPD
patients or the LCSS) is preferable. Breathlessness-specific questionnaires are more likely to
consider the sensation of breathlessness and the impact
on function, e.g. the CDS focuses on the sensation and
the distress of breathlessness. In research, it is sensible to combine unidimensional and
QOL- or breathlessness-specific questionnaires, the latter
especially if there is a wish to examine the sensation of
breathlessness and its impact on function. In addition, it is well worth considering whether a mixed
methods approach could be used e.g. a unidimensional
scale and a qualitative interview for experience and
contextual factors.
Further validation and comparison of the tools reviewed
may provide researchers and clinicians with useful means to
help the pressing need to complete research in this complex
area.
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